Cerebrospinal fluid levels of chitinase 3-like 1 and neurofilament light chain predict multiple sclerosis development and disability after optic neuritis

Multiple Sclerosis

Volumn 21, Issue 14, 2015, Pages 1761-1770

  Modvig, S ^a   Degn, M ^a   Roed, H ^b   Sorensen T L ^c   Larsson, H B W ^a   Langkilde, A R ^d   Frederiksen, J L ^a   Sellebjerg, F ^d  

^a GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

^b Holbaek Municipal Eye Clinic   (Denmark)

^c Mental Health Center Glostrup   (Denmark)

^d University of Copenhagen   (Denmark)

Author keywords

Biological markers; CHI3L1 protein; chitinase; CSF; human; multiple sclerosis; neurofilament protein L; optic neuritis; prognosis

Indexed keywords

CHITINASE; CXCL13 CHEMOKINE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GELATINASE B; IMMUNOGLOBULIN G; MONOCYTE CHEMOTACTIC PROTEIN 1; MYELIN BASIC PROTEIN; NEUROFILAMENT PROTEIN; OLIGOCLONAL BAND; OSTEOPONTIN; PROTEIN CHI3L1; UNCLASSIFIED DRUG; ADIPOCYTOKINE; BIOLOGICAL MARKER; CHI3L1 PROTEIN, HUMAN; LECTIN; NEUROFILAMENT PROTEIN L; ALBUMIN;

ADULT; ARTICLE; DISABILITY; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; EOSINOPHIL COUNT; EXPANDED DISABILITY STATUS SCALE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; MULTIPLE SCLEROSIS SEVERITY SCALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTIC NEURITIS; PACED AUDITORY SERIAL ADDITION TEST; PREDICTIVE VALUE; PROTEIN CEREBROSPINAL FLUID LEVEL; RETROSPECTIVE STUDY; SCORING SYSTEM; ADOLESCENT; CEREBROSPINAL FLUID; DISEASE COURSE; MIDDLE AGED; PROGNOSIS; SEVERITY OF ILLNESS INDEX; YOUNG ADULT; ASSESSMENT OF HUMANS; CEREBROSPINAL FLUID ANALYSIS; COGNITIVE DEFECT; COLOR VISION; CONTRAST SENSITIVITY; EARLY TREATMENT OF DIABETIC RETINOPATHY SCORE; IMMUNOBLOTTING; ISOELECTRIC FOCUSING; LEUKOCYTE COUNT; LIGHT CHAIN; PEGBOARD TEST; VISUAL ACUITY;

ADIPOKINES; ADOLESCENT; ADULT; BIOMARKERS; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; LECTINS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; NEUROFILAMENT PROTEINS; OPTIC NEURITIS; PROGNOSIS; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 84937063542     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458515574148     Document Type: Article

References (38)

1. Aloisi F, Columba-Cabezas S, Franciotta D, et al. Lymphoid chemokines in chronic neuroinflammation. J Neuroimmunol 2008; 198: 106-112.
2. Phares TW, Stohlman SA, Hinton DR, et al. Astrocyte-derived CXCL10 drives accumulation of antibody-secreting cells in the central nervous system during viral encephalomyelitis. J Virology 2013; 87: 3382-3392.
3. Mahad D, Callahan MK, Williams KA, et al. Modulating CCR2 and CCL2 at the blood-brain barrier: relevance for multiple sclerosis pathogenesis. Brain 2006; 129: 212-23.
4. Sellebjerg F, Madsen HO, Jensen CV, et al. CCR5 delta32, matrix metalloproteinase-9 and disease activity in multiple sclerosis. J Neuroimmunol 2000; 102: 98-106.
5. Hur EM, Youssef S, Haws ME, et al. Osteopontin-induced relapse and progression of autoimmune brain disease through enhanced survival of activated T cells. Nature Immunol 2007; 8: 74-83.
6. Sato W, Tomita A, Ichikawa D, et al. CCR2(+)CCR5(+) T cells produce matrix metalloproteinase-9 and osteopontin in the pathogenesis of multiple sclerosis. J Immunol 2012; 189: 5057-5065.
7. Reboldi A, Coisne C, Baumjohann D, et al. C-C chemokine receptor 6-regulated entry of TH-17 cells into the CNS through the choroid plexus is required for the initiation of EAE. Nature Immunol 2009; 10: 514-523.
8. Sellebjerg F, Christiansen M, Nielsen PM, et al. Cerebrospinal fluid measures of disease activity in patients with multiple sclerosis. Mult Scler 1998; 4: 475-479.
9. Malmestrom C, Haghighi S, Rosengren L, et al. Neurofilament light protein and glial fibrillary acidic protein as biological markers in MS. Neurol 2003; 61: 1720-1725.
10. Modvig S, Degn M, Horwitz H, et al. Relationship between cerebrospinal fluid biomarkers for inflammation, demyelination and neurodegeneration in acute optic neuritis. PloS one 2013; 8: e77163. DOI: 10.1371/journal.pone.0077163.
11. Bonneh-Barkay D, Bissel SJ, Kofler J, et al. Astrocyte and macrophage regulation of YKL-40 expression and cellular response in neuroinflammation. Brain Pathol 2012; 22: 530-546.
12. Ku BM, Lee YK, Ryu J, et al. CHI3L1 (YKL-40) is expressed in human gliomas and regulates the invasion, growth and survival of glioma cells. Int J Cancer 2011; 128: 1316-1326.
13. Lee CG, Hartl D, Lee GR, et al. Role of breast regression protein 39 (BRP-39)/chitinase 3-like-1 in Th2 and IL-13-induced tissue responses and apoptosis. J Expl Med 2009; 206: 1149-1166.
14. Comabella M, Fernandez M, Martin R, et al. Cerebrospinal fluid chitinase 3-like 1 levels are associated with conversion to multiple sclerosis. Brain 2010; 133: 1082-1093.
15. Teunissen CE, Iacobaeus E, Khademi M, et al. Combination of CSF N-acetylaspartate and neurofilaments in multiple sclerosis. Neurol 2009; 72: 1322-1329.
16. Teunissen CE, Petzold A, Bennett JL, et al. A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking. Neurol 2009; 73: 1914-1922.
17. Cutter GR, Baier ML, Rudick RA, et al. Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain 1999; 122: 871-882.
18. Lechner-Scott J, Kappos L, Hofman M, et al. Can the Expanded Disability Status Scale be assessed by telephone? Mult Scler 2003; 9: 154-159.
19. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Annals Neurol 2001; 50: 121-127.
20. Lin DY YZ,. Semiparametric analysis of the additive risk model. Biometrika 1994; 81: 61-71.
21. Youden WJ,. Index for rating diagnostic tests. Cancer 1950; 3: 32-35.
22. Roxburgh RH, Seaman SR, Masterman T, et al. Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity. Neurol 2005; 64: 1144-1151.
23. The Optic Neuritis Study Group. Multiple sclerosis risk after optic neuritis: final optic neuritis treatment trial follow-up. Archiv Neurol 2008; 65: 727-732.
24. Gout O, Bouchareine A, Moulignier A, et al. Prognostic value of cerebrospinal fluid analysis at the time of a first demyelinating event. Mult Scler 2011; 17: 164-172.
25. Fisniku LK, Brex PA, Altmann DR, et al. Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis. Brain 2008; 131: 808-817.
26. Ghezzi A, Martinelli V, Torri V, et al. Long-term follow-up of isolated optic neuritis: the risk of developing multiple sclerosis, its outcome, and the prognostic role of paraclinical tests. J Neurol 1999; 246: 770-775.
27. Rolak LA, Beck RW, Paty DW, et al. Cerebrospinal fluid in acute optic neuritis: experience of the optic neuritis treatment trial. Neurol 1996; 46: 368-372.
28. Tintore M, Rovira A, Rio J, et al. Do oligoclonal bands add information to MRI in first attacks of multiple sclerosis? Neurol 2008; 70: 1079-1083.
29. Scully S, Yan W, Bentley B, et al. Inhibitory activity of YKL-40 in mammary epithelial cell differentiation and polarization induced by lactogenic hormones: a role in mammary tissue involution. PloS one. 2011; 6: e25819. DOI: 10.1371/journal.pone.0025819.
30. Libreros S, Garcia-Areas R, Iragavarapu-Charyulu V,. CHI3L1 plays a role in cancer through enhanced production of pro-inflammatory/pro-tumorigenic and angiogenic factors. Immunologic Res 2013; 57: 99-105.
31. Correale J, Fiol M,. Chitinase effects on immune cell response in neuromyelitis optica and multiple sclerosis. Mult Scler 2011; 17: 521-531.
32. Kawada M, Seno H, Kanda K, et al. Chitinase 3-like 1 promotes macrophage recruitment and angiogenesis in colorectal cancer. Oncogene 2012; 31: 3111-3123.
33. Bonneh-Barkay D, Wang G, Laframboise WA, et al. Exacerbation of experimental autoimmune encephalomyelitis in the absence of breast regression protein 39/chitinase 3-like 1. J Neuropathol Expl Neurol 2012; 71: 948-958.
34. Lin YH, Yang-Yen HF,. The osteopontin-CD44 survival signal involves activation of the phosphatidylinositol 3-kinase/Akt signaling pathway. J Biol Chem 2001; 276: 46024-46030.
35. Bornsen L, Khademi M, Olsson T, et al. Osteopontin concentrations are increased in cerebrospinal fluid during attacks of multiple sclerosis. Mult Scler 2011; 17: 32-42.
36. Salzer J, Svenningsson A, Sundstrom P,. Neurofilament light as a prognostic marker in multiple sclerosis. Mult Scler 2010; 16: 287-292.
37. Norgren N, Sundstrom P, Svenningsson A, et al. Neurofilament and glial fibrillary acidic protein in multiple sclerosis. Neurol 2004; 63: 1586-1590.
38. Axelsson M, Malmestrom C, Nilsson S, et al. Glial fibrillary acidic protein: a potential biomarker for progression in multiple sclerosis. J Neurol 2011; 258: 882-888.